Unknown

Dataset Information

0

Leber Congenital Amaurosis Due to GUCY2D Mutations: Longitudinal Analysis of Retinal Structure and Visual Function.


ABSTRACT: Gene augmentation therapy is being planned for GUCY2D-associated Leber congenital amaurosis (LCA). To increase our understanding of the natural history of GUCY2D-LCA, patients were evaluated twice with an interval of 4 to 7 years between visits using safety and efficacy outcome measures previously determined to be useful for monitoring this disorder. In this group of molecularly-identified LCA patients (n = 10; ages 7-37 years at first visit), optical coherence tomography (OCT) was used to measure foveal cone outer nuclear layer (ONL) thickness and rod ONL at a superior retinal locus. Full-field stimulus testing (FST) with chromatic stimuli in dark- and light-adapted states was used to assay rod and cone vision. Changes in OCT and FST over the interval were mostly attributable to inter-visit variability. There were no major negative changes in structure or function across the cohort and over the intervals studied. Variation in severity of disease expression between patients occurs; however, despite difficulties in quantifying structure and function in such seriously visually impaired individuals with nystagmus, the present work supports the use of OCT as a safety outcome and FST as an efficacy outcome in a clinical trial of GUCY2D-LCA. A wide age spectrum for therapy was confirmed, and there was relative stability of structure and function during a typical time interval for clinical trials.

SUBMITTER: Jacobson SG 

PROVIDER: S-EPMC7922686 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Leber Congenital Amaurosis Due to <i>GUCY2D</i> Mutations: Longitudinal Analysis of Retinal Structure and Visual Function.

Jacobson Samuel G SG   Cideciyan Artur V AV   Sumaroka Alexander A   Roman Alejandro J AJ   Wu Vivian V   Swider Malgorzata M   Sheplock Rebecca R   Krishnan Arun K AK   Garafalo Alexandra V AV  

International journal of molecular sciences 20210218 4


Gene augmentation therapy is being planned for <i>GUCY2D</i>-associated Leber congenital amaurosis (LCA). To increase our understanding of the natural history of <i>GUCY2D</i>-LCA, patients were evaluated twice with an interval of 4 to 7 years between visits using safety and efficacy outcome measures previously determined to be useful for monitoring this disorder. In this group of molecularly-identified LCA patients (<i>n</i> = 10; ages 7-37 years at first visit), optical coherence tomography (O  ...[more]

Similar Datasets

| S-EPMC4444599 | biostudies-literature
| S-EPMC1182050 | biostudies-literature
| S-EPMC3400723 | biostudies-literature
| S-EPMC7138296 | biostudies-literature
| S-EPMC5028737 | biostudies-literature
| S-EPMC3454532 | biostudies-literature
| S-EPMC3568385 | biostudies-literature
| S-EPMC2903652 | biostudies-literature
| S-EPMC3688627 | biostudies-literature
| S-EPMC3597193 | biostudies-literature